What Fenofibrate Mylan Treats: Main Uses and Benefits

Fenofibrate Mylan is commonly used as an adjunctive treatment to diet and appropriate lifestyle changes to address specific blood lipid imbalances and their associated long-term health concerns. Its primary role involves supporting the modulation of both harmful and protective fats in the bloodstream, contributing to overall metabolic management.

The medication is indicated for the management of severe hypertriglyceridemia, primary hypercholesterolemia, and mixed dyslipidemia.

---

Key Therapeutic Contexts

This treatment is generally applied when symptoms related to systemic imbalance persist despite dedicated lifestyle efforts, often used during phases when symptoms become more noticeable. Its primary benefit involves support for managing the acute risk of pancreatitis caused by very high triglycerides and assisting in achieving a more balanced lipid profile by reducing elevated triglycerides and LDL-C, while simultaneously increasing protective HDL-C.

The medication may also be part of the long-term supportive management for adult patients with Type 2 Diabetes Mellitus, where it is considered relevant for managing the progression of diabetic retinopathy.

“Fenofibrate is applied across domains where additional symptomatic support is needed to address lipid profiles that interfere with long-term functional stability.”

Quick Fact: Relief for Lipid Imbalance Fenofibrate Mylan is used to support the management of the risk of pancreatitis related to high blood fats and contributes to general well-being during periods of systemic imbalance confirmed by lab tests.

Regulatory References

1. NIH StatPearls overview

Who Can and Cannot Use Fenofibrate Mylan?

The population eligibility for Fenofibrate Mylan is strictly defined by regulatory authorities and is primarily restricted by organ function, reproductive status, and age. The medicine is approved for use in adults diagnosed with primary hypercholesterolemia, mixed dyslipidemia, or severe hypertriglyceridemia.

---

Absolute Contraindications (Must Not Use)

Fenofibrate Mylan is contraindicated and must not be used by specific patient groups, as listed in official prescribing information:

• Severe Renal Impairment: Patients with an eGFR below 30 mL/min/1.73m^2, including those on dialysis.
• Active Liver Disease: This includes individuals with unexplained persistent liver function test abnormalities or biliary cirrhosis.
• Pre-existing Gallbladder Disease.
• Hypersensitivity: Patients with a known allergy to fenofibrate or a history of photoallergy/phototoxicity from fibrates or ketoprofen.
• Lactation (Breastfeeding): Use is prohibited due to the potential for adverse effects on the nursing infant.

---

Conditional and Restricted Use

• Mild to Moderate Renal Impairment: Patients with an eGFR between 30 and 59 mL/min/1.73m^2 may use the medicine, but a reduced initial dose is mandatory.
• Pregnancy: Use is conditional and only permitted if a physician determines the potential benefits outweigh the potential risks to the fetus.
• Pediatric Patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.

Interactions with other medicines and products

This section outlines the clinically significant drug-drug and drug-product interactions for Fenofibrate Mylan as documented in official government regulatory information.

---

Documented Interaction Categories

Interaction Type	Interacting Agent Category/Product	Regulatory Restriction
Contraindicated	Other Fibrates	Co-administration is forbidden due to toxicity risk.
Pharmacodynamic	HMG-CoA Reductase Inhibitors (Statins)	Use with caution; requires close monitoring for muscle toxicity.
Pharmacodynamic	Oral Anticoagulants (e.g., Coumarin-type)	Requires dosage adjustment and frequent INR monitoring.
Pharmacokinetic	Immunosuppressants (e.g., Ciclosporin)	Requires close monitoring of renal function.
Pharmacokinetic	Bile Acid Binding Resins	Requires specific timing separation for administration.

---

Specific Constraints and Requirements

Fenofibrate's co-administration with oral anticoagulants (like warfarin) is documented to enhance the anticoagulant effect, which necessitates frequent checking of the International Normalized Ratio (INR) to manage the risk of bleeding. The combined use with HMG-CoA reductase inhibitors significantly increases the risk of serious muscle toxicity, making caution and continuous clinical observation mandatory. The label establishes a strict contraindication against the concurrent use of Fenofibrate Mylan with other fibrates due to heightened toxicity concerns. For bile acid binding resins, an official temporal separation requirement specifies that Fenofibrate Mylan must be taken at least one hour before or four to six hours after the resin to ensure proper absorption.

Molecular Control: PPARalpha Genomic Modulation

The core mechanism relies on fenofibric acid, the active metabolite, functioning as a full agonist that binds to the Peroxisome Proliferator-Activated Receptor alpha (PPARalpha). This nuclear receptor is a key transcriptional regulator, and its activation modulates the transcription of numerous genes in the liver. This cascade directly controls the rate at which the body produces and clears various fat-carrying particles.

---

Pathway Effect: Enhanced Catabolism of Triglycerides

The genomic action produces its main physiological effect by simultaneously increasing the production of the fat-breaking enzyme Lipoprotein Lipase (LPL) and decreasing the synthesis of Apolipoprotein C-III (Apo C-III), which normally inhibits LPL. This combined effect accelerates the removal of triglyceride-rich particles (VLDL and chylomicrons) from the bloodstream, causing a reduction in circulating triglycerides and modifies the lipoprotein profile toward larger, buoyant cholesterol particles.

---

Pleiotropic Action: Non-Lipid Systemic Modulation

Beyond its primary role in fat metabolism, the mechanism also extends to non-lipid effects. Activated PPARalpha interferes with pro-inflammatory signaling pathways like NF-kappaB, thereby reducing the expression of inflammatory mediators. Additionally, the mechanism increases the kidney's urinary excretion of uric acid.

How to Use Fenofibrate Mylan

Fenofibrate Mylan is an oral medication, typically supplied as a tablet or capsule, and is designated for long-term use in managing blood lipid profiles. The medicine must be swallowed whole and should not be crushed, broken, or chewed. The timing of intake relative to meals can vary depending on the specific product formulation; some products are specified to be taken with a meal for optimal absorption, while others may be taken without regard to food.

---

Standard Dosing and Frequency

The standard pattern of use is a once-daily schedule. For primary hyperlipidemia or mixed dyslipidemia, the usual adult dosage is typically 145 mg or 160 mg once daily, although this is product-specific. Treatment should be used in conjunction with ongoing dietary measures instituted prior to therapy. If a dose is missed, patients should typically not take an extra dose but should resume with the next scheduled dose.

---

Usage Adjustments and Course Duration

Treatment is intended to be a long-term therapy, but its continuation is contingent upon objective results. Dosage adjustments, or titration, are determined based on repeat serum lipid determinations typically conducted at 4 to 8 week intervals after initiation. If an adequate therapeutic response is not achieved after two to three months of treatment at the maximum recommended dose, therapy should be withdrawn.

Specific instructions govern use in populations with reduced kidney function. For mild to moderate renal impairment, a lower starting dose (e.g., 40 mg, 48 mg, or 54 mg) is generally required. Furthermore, safety and efficacy have not been established in the pediatric population (under 18 years).

Recent Clinical Evidence Overview

Fenofibrate, the active component in Fenofibrate Mylan, is a fibrate class medication primarily studied for its ability to affect lipid metabolism. Clinical research indicates that fenofibrate, when used alongside diet, may help manage certain elevated lipid levels in the blood.

Impact on Lipids and Cardiovascular Risk

Studies consistently show that fenofibrate is associated with substantial reductions in serum triglycerides (TG) and increases in high-density lipoprotein cholesterol (HDL-C), commonly referred to as “good” cholesterol. The effect on low-density lipoprotein cholesterol (LDL-C or “bad” cholesterol) is variable, often involving a shift toward larger, less dense particles.

Two large-scale, placebo-controlled trials, the FIELD Study and the ACCORD-Lipid Trial, examined the effect of fenofibrate on major cardiovascular events (like heart attack and stroke) in patients with Type 2 diabetes. Overall, these trials did not show a significant reduction in cardiovascular mortality or morbidity for the entire study population.

However, subgroup analyses from both trials suggested a potential benefit in a specific subset of patients: those with marked dyslipidemia at baseline, characterized by very high triglycerides and low HDL-C.

---

Safety Profile and Adverse Events

In clinical trials, fenofibrate was generally studied for its tolerability. The most common adverse events reported by participants included stuffy or runny nose, headache, and back pain. Less commonly, the medication has been associated with reversible increases in serum creatinine, an indicator of kidney function, and in rare cases, liver enzyme elevations or muscle problems (myopathy/rhabdomyolysis), particularly when used in combination with statin drugs. Fenofibrate is typically contraindicated in patients with pre-existing severe kidney or liver disease.

Common questions about Fenofibrate Mylan (FAQ)

---

Q: Does Fenofibrate Mylan interact with alcohol or grapefruit juice?

Regulatory documents indicate that consuming large quantities of alcohol may increase the risk of developing liver problems when using fenofibrate. Official product information suggests that patients should be cautious regarding alcohol intake. The official product information does not typically include specific warnings regarding interactions with grapefruit juice.

---

Q: What should be monitored during my Fenofibrate Mylan treatment?

Official information requires periodic monitoring of several blood values during treatment. This includes checking liver function (transaminases), kidney function (serum creatinine), and serum lipid levels (to determine effectiveness). If used concurrently with oral anticoagulants (blood thinners), the International Normalized Ratio (INR) is typically monitored frequently.

---

Q: How long does it take for Fenofibrate Mylan to lower my triglycerides?

The active component of the medicine reaches stable concentrations in the body after about nine days of regular use, which is necessary for its intended effect. To evaluate the therapeutic effect, the official product information indicates that lipid levels are typically assessed with blood tests after 4 to 8 weeks of starting treatment. Regulatory guidelines indicate that the continuation of therapy is contingent upon an adequate response, which is assessed after two to three months of treatment.

---

Q: Is Fenofibrate Mylan available as a generic drug?

Fenofibrate is the generic name of the active ingredient, and various formulations are available as generic products. These products are approved by regulatory authorities and contain the same active ingredient as Fenofibrate Mylan.

---

Q: How should I dispose of unused or expired tablets?

Official guidance recommends against disposing of the medication in household trash or wastewater, such as flushing it down the toilet or sink. Instead, the product should be returned to a pharmacist or disposed of according to specific local pharmaceutical waste procedures.

How to Store and Dispose of Fenofibrate Mylan?

Fenofibrate Mylan must be stored according to strict regulatory conditions to ensure stability. The medicine must be kept at controlled room temperature, generally below 30 C, in a cool, dry place. It must be protected from high heat and moisture, meaning storage in areas like the bathroom or near a sink is prohibited.

Packaging and Protection

The tablets should remain in their original package until the time of use. It is a mandatory requirement to store the product out of the reach of children.

Disposal

To dispose of unused or expired Fenofibrate Mylan, do not discard it in household trash or wastewater. Instead, the product must be returned to a pharmacist or follow specific pharmaceutical waste procedures that comply with local regulatory requirements.